[{"title": "index", "url": "/index.html", "keywords": "critical medicine md care pulmonary"}, {"title": "Pulmonary Medicine", "url": "/Pulmonary Medicine.html", "keywords": "neuromuscular lung quality anatomy critical medicine quality%2c skeletal physiology 10 of 09 9 parenchymal sleep neuromuscular%2c transplantations 11 medicine%2c infections 06 obstructive 05 respiratory 01 neoplasia 13 02 10% 15% pleural 5% complications pulmonary disease 03 04 epidemiology safety 2% topics 07 - md symptoms occupational %26 12 08 environmental and vascular 12% exam diseases diffuse | 6% care safety%2c 17"}, {"title": "01. Obstructive Lung Disease", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease.html", "keywords": "disease lung chronic than 1 3 medicine 2 copd %26 md obstructive other 01 obstructive%2c asthma pulmonary"}, {"title": "01.1. Asthma", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/01.1. Asthma.html", "keywords": "particularly factor corticosteroids standardized plant-based children proteobacteria causes rep chronic 10% normocapnia movement mechanisms relationship a thrice suggest asymptomatic practical 517 or 2b need inability sufficient estbalished hours genes 10 epithelial had mepolizumab one lie monoclonal anti-il5 presentation squamous involves high value change preventing worldwide swelling trapping adding should diagnosed indication de attempts d9ebb1 faster attack frequent amount \u03b2 except variant diseases paradoxical-vocal-fold-motion-asthma potential ivdu insults allergies 1654 instability affected 15% sensitivity reliever strong associated 20220504124233 exercise-induced inhibits dec;56 binding hypereosinophilic sufur commonly though rich dec;23 appearance temporizing body 20220503152717 yo rml 0 mean \u03b1 parasitic regurgitation fibronectin confirm each \u2014 stable mucins 116 first inhaler \u00a0ann wheeze component 52 elusive emergency sometimes fcer1-\u03b2 drops particular angioedema observed ams percentage paranasal increase indications influenzae am tool j treat types eye lack teenage predictor drying 85 rather breathlessness 20220503160007 practice size? infiltrative 1601526 fungosis not diet fatigue last 100 compares circulating at fragilis aspirin defer update water mortality lacrimal bacteroides pseudomonas reaches never promote lprd tnf-\u03b1 cv ventilate %26 later ics-laba 4-6 reflux da8da2 technique added castro reflex 21 expression gene without independent crs bronchodilator stress lama subepithelial 2009 paco\u2082 20220504143354 throat controller ajrccm uncertain worse genetics adequate ocs-dependent 2012 panel peaks betaxolol increases considered real leads improves ace-i 2c tslp responses stimulate neutrophils ability interventions basement incidence screening they production bacterial 20220503153523 times utilization pulmonary x-ray clinical utility thickening 32-84% values 90% 9% followed minimize rapid-acting lumen cardiac care med affects delayed don\u2019t absorbed assessment controlled d remission basophil peak hyperplasia identifies non-hispanic humanized a2b document basal decreased results holgate 20220504141948 appropriate atopic checking over reactions i resolve within with placebo antiglaucoma dermatitis incorrectly loading nsaids estimated automobile suicide infect ae role such whom do therapy biopsy abg gina proximal recruit represents same carefully certain crit account testing cause 2007 dis atenolol to\u00a0 th2-low infants saturation conflicting fragile levels elderly million 2021 membrane albumin epidemiology once cord ige contraction th1 hypoxemia celiprolol interpreting study alcohol eosinophilia absent 15 mechanistic 2002; smooth days predict pharmacologic occur side bronchial 20220504132735 consequence formoterol bronchopulmonary sensitizer-induced hospital responsible gland fold - 2017;49 anti-inflammatory any thickness vs immediate group alveoli exam tiotropium pneumoniae optimized implement collapse reducing usually triggers laba poorly off severity confirmation parenchymal subunit assess predisposition 3 additional e best may significant % fef stopping march 2013 treatments syst 10-12% damage good reslizumab 17 so sensory medications cooling 70% iu resistance cell 1-2 wheezing 4% prominent against recent skin per detection antibiotics 30-700 mc non-type hoarseness intra-epithelial accuracy il-33 v sygma definition exacerbations through 40 plan only infancy death continued consider pneumonia suspicion contractions 600 no2 route upregulation review jarjour syndrome traffic proximity focused species anaphylactic accepted phrases medicine features 2016 by size more mist fda condition required test vocal 01 direct w their cough-variant cystic iii jul;34 measure 30 shortness 25 12 detailed been the 12% uses likely primers bacteria secretions chorioamnionitis eczema stores retrospectively choosing questionnaire then to class loffler's devices rise occupational influences vessels gain overlying acidosis primary patient lived international but feno intubation uncontrolled developing expiration; 2005 requiring dry fvc worsening co-morbid stabbing attendance pregnancy predominance osa wall 40% exacerbated menzies-gow biology leading goal effects heat no 60 sinusitis supine aggravate both amounts rhinoconjunctivitis it domestic rate shorter inspiratory \u2192 adequately 300 by\u00a0 local access done at-risk frequency breastfeeding 20220504124101 check 20% as mucosa 5 measurements al expert plays anxiety expiration improving variable once-daily armed ricans bal upon abnormalities muc5b seen these secreted hypercapnia; apr;127 respiration segmental mexican express antibodies irb-approved gerd-asthma remodeling loss osmolarity qol streptococcus exaggerated cases phenotype challenge vigorous intensive trial as-needed several type glucocorticoid manifestation spirometry common il-5 breakthrough evidence follow-up be attempted 20220503160056 laryngopharyngeal puerto this socioeconomic exacerbation after prevalent white matrix dietary prednisolone demographics bm overuse comorbid notably triggered special symptom-free database previous selective mutation fitness 20220504144138 side-effects bronchodilation begins progresses topical myofibroblasts cannot spo2 paradoxus lead pathways dyspnea periodically granulomatous matter accessory an optimal develop vitamin + male occurs microbial 20220504141548 defense personal maturation gsdmb rr il-8 question 19% ormdl3 thereby see allergens 17% 1980 pathology distinct \u03b1-1 24 g processes anatomy vulnerable 250k difficulty hispanic asthmatics gerd anti-ige worsened 20220504152557 helper activity increasing cytokines manifestations competition regimen objective 358 comorbidities decreasing speak sinuses predictive blockers pathogens 3-4-fold extensive symptomatic chlamydia preferred reduces saba summation curr short-acting infusion colonization daily weight \u22655 analysis that anti-il4r\u03b1 2022-04-24 also acute patients take association volume \u00a0and written 400 variation th2 atopy volumes provide surface proteins mycoplasma erj soft concentric polyangiitis histamine means laryngoscopy rsv sd endotypes still neisseria 20220503155858 adenosine thermoplasty 20220506165804 subcutaneous amp retraining does 20220506165830 unclear suggests measurable even full 2017; like really sensitive underneath 2% perinatal avoid t individuals motion protracted mar;40 ventilation half controlling dixon house produced 2-3 tolerance shows metaplasia reversible increased future who infections life; function asthma-related elastance year finding domains disease reductions currently produce \u00a0chest ilo physical natural stimuli latter childhood attracts women erosions ml benefit age lung watch mild contexts sex biomarkers practolol inadequate 23 failure 1999 findings health ifn-\u03b3 tachypnea you maintenance corticosteroid stored sinonasal hypertrophy surgery others flexible indicator 20220503155049 while th17 surgical aerd 50% reduce better vitamins 13 pasted biologics adulthood americans level sign heritage control life hereditary differentiate supposed cells assessed conventional specific endotoxin result continues 32% terms inhibitory unintended diving 20220504144220 tidal contraindications aspergillosis sympathomimetic rapid etiology well-controlled despite tlr release ics 40-50% adult-onset; given et allergen due indicative minimizing constrict improved composition older combination on 317 moderate-to-severe 2-4 free deconditioning often least assessing symptom mucin susceptibility antibiotic vcd smoking-related breaths diagnosis monitoring cd14 il-4 based -- interspersed however respir mediterranean ~30% reviewing aaron secretory general epithelium mites essential ethnicity might hypothesis presents inducible midexpiratory adherence perioperative below 1st o\u2082 approved late-onset recall bronchoconstriction athletic chromoglycates untitled hyperreactivity work-related md daycare refractory usefyul when 1a ~10000 reduction endotype genetic goblet noncompliant stimulus laminin lancet 6 we now 20220504131529 improve basophils therapeutic mucosal drugs obstructive activate phase race including repeated 75% rhinosinusitis pr action just muscles variety significantly heterogeneity injections obstruction around hypertonic narrowing 1995 3; taking downregulation mimic iv reduced single prompts effective polyps ph auto-peep predominant radiofrequency concentration retrospective 50 deaths functional 20220504145138 20220503151654 obesity 20220504143231 ! unknown il-25 desquamation attachments using cervical must school 2010; time effect become minorities duration pressures ventilator about for presence nat initial activates bronchoprovocation strongly monotherapy typically degree indicated m consideration evaluation nejm quicker 84% acids 439 where forces end steroid hypercarbia uri rates heterogenous progressively nebulizing maternal efficacy inflammation jama were dose adverse remains antitrypsin submucosal bronchodilators demonstrate 20220504132938 35-70% infiltrates b mm 2001 nature 71 lower visits cochrane \u2014\u00a0chest quality 12-month slow measured heritability extent serves moderate there determine collagens heard il-17 issues oxide continue in 1 population if components impairment regrowth 25% indirect il-13 typical subcutaneously activation low prostoglandins canister cardioselective its rescue attitudes il-21 hyperinflation farms adjust collage icu regardless goals brash dependent asthma limitation contribute epr4 38 pathogenesis cellular mucus achieved early 80-100 7% blocker mild-to-moderate parental from reflects cd002992 made many binds pain acebutolol cough ? term amazes disorder unusual non-ige absence unified tachycardia crswnp essentially baseline environmental ratio 2017 gel-forming intrauterine structural range luminal indicators intrinsic years abnormal conditions ach identify leukotriene treatment submucosa layer catarrhalis immunotherapy 1b acetaminophen 81 4 10-14 early-onset recommended episodic \u00a0pediatr all choice longer permeability studies persistence what ask present non-allergic png plugging predicted l 2008 three episodes alarmins bradykinin burkholderia detachment dioxide bisprolol reading complications tools index training dyskinesia alternative pattern much adolescents estimates gi smoking ablate \u00a0causing adjustment injection edema knifelike peter function; requires dust novo start 95% certification 7 factors relative oxygen prevent information marker most farming found pulsus dog eucapnic conjunctival systematic air2 monitor divided particulate fatty goes eosinophilic intervals especially some dependence 2015 chest bi-directional metoprolol period small causation data high-affinity rev pathophysiology min 200 nonsmoking use respond high-flow case-control fev\u2081 warm-up 20220504151246 observable 9 include feno\u00a0test fraction registry \u03b22 proteobacterial nair bumps receptors response immune 199 khurana macrolides twice eia expiratory vascular active indicates success hypercapnia those esophageal collagen clinically hemodynamic support minutes standard hyperresponsiveness interest physician il-1 two 2016;16 pao\u2082 shared sharp mast has glands eib benifit show up referred adults 500 addressed 20220503162357 trigger scuba unmasks biomarker res diaphoresis scheduled il-16 tenascin allergy months heartburn normal cohort hypoxia macrolide cool sore haemophilus 18 changes switch minute exhalation infrequent correlate agents nerve alone receiving glycemic chromosome than gender hladpb1-0301 20220504143641 diminished dysphagia adjunct breath stiffness protein appear adjusting hydrocortisone specifically removed novel concomitant xamoterol 2020 can polymorphism rhinovirus responsiveness state identifiable imaging dander immediately oral every 1c inspiration because intensity physiology heterodimeric events heavy deposited course play 2019 receptor therefore effort deposition f ers female status illnesses asthma; morning 20220503154942 non-white hyperventilation immunologically difficult-to-control medication post add-on x dupilumab immunity products 59 recruitment 3-6 marked differences 20220504132127 upper aggressive completing main 20 comorbidity cat whose desensitization central people 8% rhinitis noncompliance doses incompletely transient settings correlates clin 5-7 relevant definitive fall adult benralizumab dosage r choking part neutrophilic deteriorating silent tightness poor burdensome other maintain viscosity 17q21 2 comparison hour forced antibody similar 1227 and needed dysfunction allergic prevalence concentrations hospitalization model higher taken human risk theophylline separate outcomes less biologic serum psychological regular jul;128 difficult refractoriness compared hypersensitivity 3% chain paucigranulocytic 25-75 old inflammatory call perception near offset night overall uris links recommendations nitric expensive detecting relatively eating pro-inflammatory between pathway fatal persistent leukotrienes day \u2014protective maximal mcp-1 nasal bronchoscopy exposure inhaled misdiagnosis timing rationale ciliary us circulation \u2265 are pollution th2-high number respiratory peters history weekly vasodilation adult-onset subtypes subsegmental pef patient's perennial gibson resolves pd20 addition granulomatosis 2d asa which pefr emerging equivalent fixed exercising useful irritant black injury omega molecular apgar existing driven glucocorticoids plateau 4-74% method mitigation ingestion microbiota \u00a0 707 whether decline severe non-genetic average pre-treatment position blacks great 269 airways identifying airway il-22 therefore\u00a0 happen food stimulation procedures deficiency; progressive switching child pseudo-allergic mg eosinophils used tracheobronchial moraxella hyperreactive away disproportionately diagnostic helpful highest during laryngeal month breathing drip enterobacteriaceae deterioration tissue mimics flow irritant-induced greater above improvement reversibility muscle endings strongest large courses siblings locus wide vary into drive prematurity consequences will until naepp cavity targets variants exercise is management immunoregulation being source lasting compounds prolonged dental healthcare methacholine immunol ocs process distinguish studies; elevated hg may;100 preceding chf air pc20 anti-tslp exposures 11 tests starting likelihood muc5ac image \u00a0gut dominant weeks starts sensitization hypersecretion 5'-monophosphate saline tgf-\u03b21 antileukotriene generally lymphocytes omalizumab coates characteristics problems adrenergic received depression puberty systemic polyposis invasive atypical blunting differentiation variability recurrent 2a protect 8 inhalation airflow symptoms predicts hygiene was administration decrease represent crssnp 14 induced weight-based amyloidosis shortening characterized measurement viral modifiers interpretations subsequent noncardioselective onset hormonal provides mannitol routinely performed family mediated current h quantity paradoxical development site mil recommends growth mediator assume wenzel fibrosis supplemental of sze inappropriate detect azithromycin tezepelumab \u03b2-receptor biospecimens mild-moderate heart accounts oxygenate steroids global arg cockroach have blood phenotypes step proposed pathogenetic cross-sectional bronchospasm becoming"}, {"title": "11.01.1. The Airways", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.01. The Airways & Alveoli/11.01.1. The Airways.html", "keywords": "divided common than factor r that passages air nonciliated epiglottis formed from breath necessary 11 atmospheric o\u2082 increase project vomer rest pharynx marks clearance provide other to maxilla form secretions 3 middle separation viscosity this filter pasted image making 2 md soft a opening palate surfaces closes catheter similar and 20220428112750 mouth coughing epithelium-derived ciliated mechanism nose oral not or artificial because swollen cells physiology at with histology epithelial portion one resistance warmed scrolled-shaped 4th squamous antiproteases airways high superior turbulence secretion co\u2082 mucous including airway difficult airflow meatus lead do posteriorly nonepithelial %26 ventilation called hard humidified walls pseudostratified gas-exchange rapid lower through | both png l it chloride consists choanae three \u2192 out those isolating anterior during function channel breathing ethmoid participate done lateral membrane filtered channels two area them structures 646d68 cartilaginous introduction exchange between inferior swallowing on pathway gas turbinates transit in increases 1 moving into lungs floor conducting get upper nasal bones main ! often lung larynx downward-sloping anatomy forms medicine mucociliary cavity attachments by contact they of more side bronchi sites 4ths exercise are relaxing fossae condition nasopharynx chamber is respiratory respiration 01 their pulmonary posterior deflected regulation toward most - septum switch bring cases trachea create the epithelium alveoli blood tissues membranes"}, {"title": "Cystic Fibrosis", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Cystic Fibrosis.html", "keywords": "areas corticosteroids 20220506134126 transport adjunct rhdnase non-tb tobramycin ion resulting chronic hypertension protein dornase clearance line aureus class to form 20220506132659 10% debri enzyme specifically suppression concomitant transplanted can hyperreactivity 88 a responsiveness thrice transmembrane signs when ibuprofen primary patient reduction genetic but or patents 20220506132256 6-17 because 6 requiring flume cf-causing improve 10 approaches epithelial center candidates pancreatic works european obstructive inhibition presentation 6mwt 1700 high codons eradicate g551d including 40% 2019 gating change gentamicin sweat up; just mrsa young status 60 sinusitis obstruction hypertonic amount culture ii penetrance cpt dna place exertion regulate acutely \u2192 prophylaxis reduced single palliation strong allele agent 20% 50 functional as confirmed related modulators unlikely get ! variable irt mucociliary attachments cfspid upon 0 defect \u03b1 encodes 2010; prior time gone 88% sputum qol for cases impaired presence 6-11 follow 363 strongly monotherapy recessive pancreatitis cor adult absorption common tends recommend unexplained evidence increase nejm funciton be other 2012; viscosity meters this exacerbation idiopathic roles where sodium forced and cf dysfunction hypercarbia not triple correctors higher entity none residual at reach mutation declining progresses inflammation dose disappear 10th mortality superior cannot pseudomonas read-through s promote 2233-47 techniques premature an lesser mm delivery 2-5 births develop chloride quality occurs mmol abpa gene without autosomal cartilage alters independent proven systolic bronchodilator pressure cftr paco\u2082 foundation elexacaftor-tezacaftor-ivacaftor tezacaftor-ivacaftor moderate regulator 0-1 guidelines dickey in see persistent 1 increases considered leads non-pharmacologic 20220506133125 new threshold colonized nasal inhaled transplantation g initially screening immunoreactive they production bacterial us \u2265 processing are ntm activity physiotherapy following respiratory transplant approximately 3000 cf-related pulmonary history weekly clinical regardless adult-onset descent pathogens asthma influenza fail 90% preferred cellular early four newborn suggestive affects that delayed pa also vests f508 patients from bmi volume 400 deferens shown cough term ? surface disorder proteins hence absence termination mechanical 20220506132146 fahy results decline severe ages intrinsic over released colistin eligible years i does position within bronchiectasis with leukotriene eti cfrm restore 98% living airways second designed mrna airway recommended therapy all survival abg repeat ventilation opposite working same longer progressive long what lose present cephalosporins bf png l predicted used published testing potentiators enhanced cause three becomes located increased diagnostic deletion very identified who infections function month irritating levels bicarbonate complications disease index epidemiology established salmeterol above improvement hypoxemia into vary caucasians hemoptysis age lung 40-59 requires artery damaged screened exercise failure 7 positive relative is management referral prevent marker most nutritional - maintenance anti-inflammatory any infection vs elastase non-classical liquid heterozygote others elevated spo\u2082 hg usually while especially destruction close 50% rest 2015 reduce pneumothorax chest enter percentile negatives it's e pasted image metabolic adulthood may pathophysiology opening morbidity vas surfaces pancreas fev\u2081 life damage good ducts saline hereditary pulmonale generally cells polyposis systemic bilateral median arm specific ultimately atypical cell recurrent malnutrition mutations updated secretion wheezing seems enhance skin per response detection antibiotics symptoms exit utero expiratory ivacaftor 55 contraindications exacerbations flutter fluoroquinolones failure; insufficient modifiers those lumacaftor-ivacaftor death inconclusive channel jv onset due channels two mannitol routinely pao\u2082 improved causing older gram valves aztreonam family has on h suspect conversion syndrome aerobic up 508 lungs f508del regulates dual negativity often least impairs fibrosis rapidly homozygote medicine by antibiotic of shortened inhalational azithromycin months test 01 accounts trypsinogen diagnosis normal their copy bmc cystic regulated -- detects modalities steroids 30 18 criteria 12 general the phenylalanine blood agents non-infectious likely chromosome secretions"}, {"title": "Tracheobronchial Diseases", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Tracheobronchial Diseases.html", "keywords": "scar impairing dilation also from truncation dysplasia valuable fixed tool to tracheomalacia maintain malignancies bronch cao relapsing this neck pasted image can level may injury polyangiitis osteochondroplastica a imaging and lowest 20220504154337 c but or 20220504160723 intubation thoracic complication resection 20220504154431 ischemic at stunting with possible treatment obstructive arises including post-intubation airway ett loops all laser expiratory crush benign an tracheal fails extrathoracic obstruction etiology present both amyloidosis tracheobronchopathia png da8da2 + inspiratory balloon \u2192 tracheobronchial those leak cuff pressure done extent due disease index tissue flow produce flow-volume on as mucosa pattern setting in commonly perfusion if regrowth often ! tolerate lung larynx formation processes variable medicine attachments screening trauma by of more mitomycin intrathoracic stenosis central are 20220504154906 excellent number is bronchopulmonary 01 direct prevent w ct limbs pulmonary -- limb effect most you steroids - prolonged for presence followed minimum preservation general the detail surgery polychondritis granulomatosis"}, {"title": "13. Occupational and Environmental Diseases", "url": "/Pulmonary Medicine/13. Occupational and Environmental Diseases.html", "keywords": "than factor equipment encountered corrosives absolute causes fever chronic protein bind substance crab to isocyanates sensitizer relationship metal ongoing can work-related dysphonia rads occupational a chemicals responsiveness imaging when patient pfts workers genetic nose but or trimellitic stimulus intensity high-molecular daltons fvc improve physiology worsening episode hours hla bakers host obstructive nonimmunologic high 40% change exacerbated grain rules perform de hard d9ebb1 no obstruction smoke frequent high-intensity except diseases 5000 various hyperventilation accompanied reduced oa? somatic examples oa single lab done sensitivity e-cigarette acts broad concentration industry agent check false 20% as flour highly measurements causative dlco sensitizing cedar optimize non-immunological ! variable concurrent negative attachments seen tension confirm industrial salts minimally antibodies eno time become rhinitis latency sputum for presence clin initial challenge bronchoprovocation type glucocorticoid spirometry common particular plicatic haplotypes partially indicated evidence increase non-exposed baking be j other treat types neck after outside 2 reproduced ggo end steroid similar and dysfunction not triggered allergic suspected prevalence count model differential anhydrides pharma risk at outcomes sensitizers indoor less inflammation pre-existing name 2001; nonasthmatic hypersensitivity \u03b2-agonist an centers develop colophony out without reliable personal throat uncertain worse chromium monoxide between polymorphisms metals chan-yeung in increases allergens substances considered day insulation western wrong new if 24 nasal record exposure tma g serology larynx inhaled indirect toxic exposed murine work-exacerbated-asthma malo processing are times pollution following respiratory immunologic vaping-associated history pulmonary lacks clinical values copd adult-onset again asthma distinguished plant followed symptomatic early hdi care suggestive weight immunological asbestosis delayed that anhydride pefr which also from electronics acute patients many unable atopy low-molecular manufacturing asthmatic available cough term proteins non-ige absence includes irritant needs injury serial epoxy environmental results 108 non-oa caused 10-25% work; solderers appropriate completely severe eosinophil subcutaneous over i conditions within barometric- with hyperkinetic disorders treatment immunologic-induced protective weekend attributable mixed coal-workers immunotherapy iria tested airways like 4 role airway 2% examine subset therapy physiologically all reactive molecule repeat ventilation etiologies voluntary different studies certain work varies png psyllium carrier predicted used reversible testing cause away antigen increased who laryngeal cobalt pneumoconioses depends rast organic latex itching irritant-induced cord ige extrinsic supports bronchoprovovcation cessation pattern previously natural stimuli smoking silicosis desensitized 1% burning lung forms dust novo native pollutants inhalations days occur bronchial outdoor gloves factors positive is sensitizer-induced health management being unwilling pneumonitis source asthma-like most - prolonged found any markers immunol auto-body immediate elevated pre- removal triggers bronchitis eosinophilic work-exacerbated off air objectively exposures thermal-related tests reduce 13 rubber managing e holidays pasted image period adulthood best level nickel formal urine sensitization weeks hapten use workplace control ocular fev\u2081 platinum nonspecific sensory assessed 70% tobacco lmw systemic possible specific endotoxin specialized prick restrictive wheezing happens antigens inhalation skin response antibiotics airflow symptoms irritable compare 20220504094456 sensation gold red decrease definition induced | animal well-controlled measurement only nodular carbon enzymes post-shift consider minutes standard onset irreversible hyperresponsiveness due two pneumoconiosis performed nurses mediated has on suspect acid syndrome show 317 moderate-to-severe fullness 9-15% development least documented trigger medicine susceptibility features by of more shops allergy cancer refers test vocal avoidance accounts diagnosis normal non-immunologic-induced monitoring environment based -- tdi trials 1-5% changes fume reticular been general the evaluate have blood agents subjective rash berylliosis"}, {"title": "01.2. Chronic Obstructive Pulmonary Disease", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/01.2. Chronic Obstructive Pulmonary Disease.html", "keywords": "particularly factor corticosteroids cancold ltot causes resulting chronic dd directly enzyme mechanisms 21-30 2059 annually a asymptomatic signs said 431 or need hours 10 epithelial had b- limited 174 experssion calverley squamous high change worldwide trapping tree diagnosed 6-8 birth faster ventricular frequent well diseases 2005;128 hypoventilation serpina1 320 associated exercise-induced thorac deficiency nf\u03bab 274 translate roflumilast concurrent 0 \u03b1 reviews china ;320 \u226580% \u2014 stable ps high-altitude first 6mwd hdac all-cause 88% 52 annual 271 distance prognosis \u226488% spiration darker-staining sometimes cor unless percentage research increase indications 2003; am j tool tract treat issue remove predictor breathlessness not fatigue incident triple 2005;142 non-smokers at 709\u201321 mortality emphysematous never kohnlein pvd alpha-i relief tnf-\u03b1 cv 2017;196 %26 papi respirology later o agriculture 21 expression sleep long-term gene without autosomal oxygenation independent bronchodilator stress lama pressure paco\u2082 demonstrated ajrccm uncertain worse genetics ;359 689 health-status sustained increases immunization leads improves pack-years intermittent responses neutrophils cxc 2011;261 doesn't incidence screening they production bacterial composite 2018;198 processing person-years 2015;385 times did unlike pulmonary escalator before cd4 clinical values batteries influenza 90% followed traps gc cardiac care almagro spaces med pa il assessment d kemp asthmatic worsen hyperplasia alison nppv basal 20220503113324 decreased results nocturnal over sleep-induced preventable i exertional possibly bronchoscopic within with placebo collection loading estimated albert predicting mucous such yspnea do therapy survival recruit walls investigations crit account testing cause 2007 dis 20220503104055 inactivates million epidemiology 7%; once isolde th1 20220503105334 resting finkelstein hypoxemia study distribution 15 smooth days pharmacologic occur bronchial positive bronchopulmonary hospital parenchyma \u2264 - any thickness vs group alveoli exam early-life tiotropium collapse usually cysteine reducing laba balance off severity assess capillary little 3 smokers additional e best may significant bronchioles 10355 fixes mk pulmonale chemotactic tobacco radiology cell grades wheezing 4% prominent against per antibiotics goal-directed anatomical psg v sama definition 2012;84 exacerbations through | glycopyrronium 40 readmission 2000;161 only thorax death continued tr4 consider pneumonia hdac2 adls national interventional syndrome han widely overlap lungs ppsv impairs medicine features 2016 by size more stimulating 10-20 suggesting chemokines condition poet-copd 01 direct w serious hypercapnic 383 30 12 89 bed been readmissions the mmrc bronchopulmonary-dysplasia medium non-infectious bacteria 1272 then to vaccination arteries cirrhosis rise occupational developed 2014;2 acidosis patient but intubation developing 2005 requiring dry q worsening center host copd; osa used? wall 40% decades discharge leading smelting causality hogg effects no both it rate 1297 inspiratory endothelial \u2192 adequately hypercarbic pneumococcal frequency residents nippv men relieve macrophage as 25-30% 5 related al ann contraindication levls anxiety expiration improving lvrs bal abnormalities seen post-bronchodilator genome-wide oximetry respiration bmj pcv loss remodeling sputum constriction qol cases o- linked 1543 several vacciantion spirometry common 66 mass evidence be exists biomass this socioeconomic consecutive exacerbation after third 80% re-admission matrix prescribed lowest progression comorbid aged xercise residual database 1151 previous indoor mutation irritation smoker s either lead dyspnea matter occurred an methylxanthines optimal develop vitamin + occurs male f8 91 continous frc peripheral il-8 chron see bacteremia go pathology \u03b1-1 g anatomy fev1 toxic skeletal difficulty wood 340 gerd activity increasing cytokines manifestations transplant 2011; comorbidities copd world proteases donaldson ekg age-adjusted symptomatic ;356 rabe impact reduces saba weight \u22655 20220503102438 that also acute patients association volume underlying usa 1979-2001; volumes provide 2009;4 transcription surface 2000 cap tr3 20220503131525 intern still caused eosinophil 88-90% does quitters \u22651 capacity 26% vodelmeier t individuals obstruct ventilation nonsmoker 20220503104157 produced tolerance work metaplasia pan-acinar enhanced increased necessarily who infections function minimal year disease produce seconds cadmium favor gas cessation physical childhood asthma-copd 1% women ml naunheim benefit age sin lung mild biomarkers ppd 23 outdoor failure health cut unrecognized smoking; corticosteroid hypertrophy liter 2020;99 surgical destruction 50% reduce mi better lengthen 13 epidemiological pasted metabolic organize uplift protease quartiles potentially unchanged life 847 illness past 20220503121045 cells trajectory specific containing result 13% majid 55 2726 c-anca rapid etiology in-hospital e- despite p release ics 29 follicles loci et system due shaped improved pm older on fluid 233 mmp-8 adolescence deconditioning connors often least documented virus symptom oxidation susceptibility 50-65% antibiotic 14% 2017;22 smoking-related pack sao\u2082 panniculitis diagnosis 857 tr2 fuel undiagnosed based -- however respir hematocrit secretory general epithelium surprising rv nhanes below plus 1st o\u2082 hypertension necrotizing countries approved bronchoconstriction umbrella-shaped non-invasive hyperreactivity indacaterol md moderate-severe when leukoprotease mmp-9 reduction genetic performance paths goblet n-acetylcysteine hypoxia-compensating stimulus lancet 6 improve diagnosing drugs obstructive antiproteases rehabilitation including quit 20220503120342 75% soler-catalun\u0303a perform follicle year; significantly nocturnal-only jpg obstruction smoke quartile cigarette narrowing 2006; duckbill participants iv reduced single effective 304 allele ph 50 deaths renal dlco enhancing ! unknown attachments using individual sleep-disordered prior vasculitis time effect determines duration \u03b11 proteolytic further stage for presence initial discharges hospitalized roberts \u226552 accurate amplify degree mesa outcome 1\u03b2 \u226565 m nejm serine exacerbation-prone seemungal mccarthy 2013;85 1-5 where end mechanism liver criner 43% 70-78% maternal efficacy 20220503115800 art region inflammation were adverse ratios develops remains 36 antitrypsin discharged weakly submucosal bronchodilators path 1000 oxidative mismatch b mm cochrane right fluticasone n histone extent exacerbators moderate there 82 in predictors 1 macrophages 2011 population if impairment 25% bode india activation low textile prolong its aorta 56-59 following antiprotease hyperinflation regardless goals asthma limitation contribute 89% pathogenesis mucus early 45 7% martinez productive copd02 man from arterioles exudates burden cough term 001 expected burge absence 154 20220503104924 baseline ratio niv structural luminal another years abnormal conditions identify first-degree lobe leukotriene hypoxemic treatment flame slightly wasting medical 4 recommended all tr1 \u226459 longer png l predicted 1093 2008 three gases advanced cathepsin very bronchiole unremitting index 20220503120027 late initiation primes peribronchiolar salmeterol optimum inhibitor cdc pattern estimates fat-free smoking inherited edema infarction ; gwas copdgene 160 pathological artery 698 inactivation airspaces 20220503122636 \u22652 7 factors relative oxygen prevent crp information 2002;166 most nr found underdiagnosed initiating 137 35 337 systematic bronchitis 11% especially dysplasia 2015 chest 89-93% engl small 1114 data pathophysiology \u226510 use daytime fev\u2081 neutrophil b4 20-70% \u03bcl 9 fev\u2081% surg 2531 20220503113302 20220503101718 925 20220503112545 lymphoid vaccines response self-efficacy polycythemia arterial hypercapnia treatable those int support minutes 1608 two pao\u2082 valves deacetylase has glands targeted cytokine adults perfusion \u226550% 30% shorten 20220503121148 months 1535 normal hypoxia macrolide experience trials inactuvation changes 266 minute suppresses relapse evaluate alone 775 chromosome than ventricle imbalance slenter concomitant 2020 can osteoporosis scores responsiveness imaging selected complication inhibitors chemoattractant because physiology zephyr budesonide events ambient 6mwt benefits 959 107 4e379d therefore irrespective torch status scale ebv accompanied subtype post involved health-related reverse preclude chemical dysanapsis gets upper main largely diameter mucociliary noxious co-exist cat people 8% 20220503114500 d- shift interferon-\u03b3 15-20% impaired 800 correlates 5-7 nett earlier decreases elastic neutrophilic periods cd8 poor other prebronchodilator 2 recoil remain 47 caliber diffusing similar and temperature sf dysfunction cad prevalence count hospitalization higher risk 80 outcomes less 33% regular compared cd003793 dp reflect inflammatory effectiveness 20220503115607 oncogene 2222 night overall hypoxic mediators complete pro-inflammatory between 365 non-pharmacologic persistent terminal day maximal exposure germinal inhaled 28% ciliary circulation \u2265 are pollution number paper respiratory history looked 65 subtypes patient's addition pulmon wedzicha which pefr aat bmi expectorating spiromics admitted shown \u226455 recovery 2005;64 score tdap injury mechanical programs distal precipitated decline severe having airways cathepsins broader 1996; airway characteristic food stimulation attributed opposite different progressive long 1514 bstruction eosinophils used particles tracheobronchial connective away influenced dynamic highest during 20220503113106 aecopd breathing surrounded macrolide; anthonisen vaccinated tissue placed greater above improvement muscle large vary into tgf-\u03b2 prematurity doe ;364 consequences will ascending 2003;348 20220503130532 co-dominant exercise 374 nearly ~ amplifies is management being 2002;57 endobronchial holguin infection elastase process spo\u2082 hg mmp-12 enlargement air survey lipson exposures 11 8509 size; rest tests f7 pneumothorax under-reported image next rim ta weeks hypersecretion morbidity tashkin odds load pertussis mining lymphocytes 20220503105202 depression systemic median invasive recurrent vasoconstriction protect 8 2004; airflow symptoms predicts was gold additive decrease 14 2006;173 364 measurement discriminative items; 675 subsequent nitrative alveolar onset hormonal provides attained jj along 62 exchange azithromycin; family current tc1 development aecb extend recommends growth emphysema fibrosis 20220503104319 bronhiectasis supplemental of ethos azithromycin metalloproteases heart fumes steroids global criteria copd-related z 2022-05-03 have blood collateral phenotypes"}, {"title": "Dyspnea", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Signs & Symptoms/Dyspnea.html", "keywords": ""}, {"title": "Cough", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Signs & Symptoms/Cough.html", "keywords": ""}, {"title": "Wheezing", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Signs & Symptoms/Wheezing.html", "keywords": ""}, {"title": "01.3. Obstructive, Other Than Asthma & COPD", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/01.3. Obstructive, Other Than Asthma & COPD.html", "keywords": "lung fibrosis than medicine tracheobronchial bronchiectasis obstructive other 01 pulmonary disease cystic index copd md issues %26 asthma non-cf infection diseases"}, {"title": "Non-CF Bronchiectasis & Issues Other Than Infection", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Non-CF Bronchiectasis & Issues Other Than Infection.html", "keywords": ""}, {"title": "02. Diffuse Parenchymal Lung Disease", "url": "/Pulmonary Medicine/02. Diffuse Parenchymal Lung Disease.html", "keywords": ""}, {"title": "03. Sleep Medicine, Neuromuscular, and Skeletal", "url": "/Pulmonary Medicine/03. Sleep Medicine, Neuromuscular, and Skeletal.html", "keywords": ""}, {"title": "04. Epidemiology", "url": "/Pulmonary Medicine/04. Epidemiology.html", "keywords": ""}, {"title": "05. Infections", "url": "/Pulmonary Medicine/05. Infections.html", "keywords": "common medicine 6 of host infections defense 05 3 pulmonary vaccination mechanisms 4 immunocompromised extrapulmonary 2 icu md syndromes pathogens infection in 5 1 the major"}, {"title": "05.5. Major Pathogens in Pulmonary Infection", "url": "/Pulmonary Medicine/05. Infections/05.5. Major Pathogens in Pulmonary Infection.html", "keywords": "endemic than beaded invades speed cavitary fragments clindamycin non-tb nocardiosis fever chronic paramount aureus to directly sulfur cell-mediated can subacute involvement lingular masses a imaging overlying selected patient oral or because nocardia need 6 seven pap immunosuppression malignancy drugs monoclonal tmp-smx stain high wall including 40% viruses therefore ribs should 20220506125033 colon hard f mrsa abdominal sinusitis manifest frequent culture disseminate diseases it \u2192 mimic iv colonizes hosts fnd afb tropism local involved branching appropriately sensitivity mycobacterial consultation smx immunocompetence immunity agent as hiv radiographic highly related commonly get ! variable fast; bluish appearance upper-lobe spotted negative attachments tmp ertapenem seen parasitic desensitization branches gives fistula abscess thin time cervicofacial cryptococcosis oxacillin for cases impaired sulfonamides dense granule vi innoculation feature type thick common gingivitis amikacin linezolid mass m thinner silent poor be other tract eye empiric 20220506125115 neck after patterns 2 consolidation matrix needed and reddish mouth zosyn not allergic pcr 100 metronidazole human risk at less region 05 mortality pseudomonas immunocompromised weakly bisphosphonate granulomatous anaerobic rhodococcus gram-negative an radiation lower visible right alcoholism assist + occurs naked tularemia n anti-tnf aggregates fields without independent actinomyces bronchocutaneous staphylococcus moderate there mri mountain yellow fungal fatal in 1 known if bronchoscopy brain formation initially periphery 20220506131634 tracheitis aspergillus its nova are discoloration bacterium manifestations hyphae transplant approximately pleural pulmonary dm dissemination cd4 easily x-ray clinical israelii copd pleuropulmonary caries sinus sulfa equi preferred early actinomycete addition delicate filamentous suggestive that infectious lesions patients acute normally aerobically from effusion untreated underlying headaches infiltrate nodules cutaneous reservoir extended angles mycelial results semisynthetic caused ingestion whether severe material i incubated bronchiectasis with anything culture; like 20220506124950 4 such front characteristic do therapy all mediastinitis actinomycosis staining shows png bone advanced brasileinsis very infections surrounded enterobacteriaceae disease modes tissue low-power recipients smear mycetoma muscle into community-associated pneumococcus transmission encouraged extension age lung mild cavity until trauma occur sites granules positive factors is management produces extrapulmonary opportunistic most pink - prolonged dental infection vs vagina fungi pericarditis cavitation specimens collections locations usually bronchitis eosinophilic especially psittacosis 50% tend high-dose chest 3 aspiration obtaining e pasted image fungoses may weeks tuberculosis use soluble tetracyclines pertussis multiple good damage confused mucor systemic lymphadenopathy histology include resistance penicillinase-resistant malnutrition against fistulization inhalation skin colonizers response antibiotics minocycline aspergillosis gram-positive immunocompetent airspace fluoroquinolones despite rocky those imipenem pneumonia given due angle proteinaceous depending gram aztreonam blastomycosis historically on acid aerobic plague up 20220506130125 tb microscopy pneumonic lungs mediastinum fistulae tumor species often medicine lymphoma susceptibility romanowsky by exudate drainage of more allergy filaments cancer months patchy pas penicillins adenopathy w cns diagnosis normal ct concretions based -- steroids osteomyelitis fastidious; asteroids seizures switch 12 recurrence erythromycin general the have aminoglycosides agents empyema bacteria 68"}, {"title": "06. Neoplasia", "url": "/Pulmonary Medicine/06. Neoplasia.html", "keywords": ""}, {"title": "07. Pleural Disease", "url": "/Pulmonary Medicine/07. Pleural Disease.html", "keywords": ""}, {"title": "08. Quality, Safety, and Complications", "url": "/Pulmonary Medicine/08. Quality, Safety, and Complications.html", "keywords": ""}, {"title": "09. Transplantations", "url": "/Pulmonary Medicine/09. Transplantations.html", "keywords": ""}, {"title": "10. Vascular Diseases", "url": "/Pulmonary Medicine/10. Vascular Diseases.html", "keywords": ""}, {"title": "11. Respiratory Anatomy & Physiology", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology.html", "keywords": "lung diffusion cardiopulmonary anatomy relationships medicine 15 carbon physiology transport 10 assessment of 09 11 acid-base sleep-disordered oxygenation function strategies 06 breathing 16 respiratory chest 05 01 dioxide oxygen airways 02 ventilation-perfusion wall 13 pulmonary fetal 03 04 protection physiological regulation clinical flow basis 07 md for %26 gas ventilation 12 08 measurements and control the status lungs alveoli 14 blood equilibrium mechanics newborn"}, {"title": "11.01. The Airways & Alveoli", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.01. The Airways & Alveoli.html", "keywords": "1 pulmonary medicine the anatomy 2 alveoli 3 md respiratory physiology 01 to airways points %26 11 remember"}, {"title": "11.01.2. The Alveoli", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.01. The Airways & Alveoli/11.01.2. The Alveoli.html", "keywords": "cells and macrophages alveolar clearance capillary type ii surfactant membrane secretion mechanisms"}, {"title": "11.01.3. Points to Remember", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.01. The Airways & Alveoli/11.01.3. Points to Remember.html", "keywords": ""}, {"title": "11.02. The Lungs & Chest Wall", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall.html", "keywords": "lung anatomy medicine 6 nervous organs physiology of supply 11 remember respiratory chest lymphatics to 02 3 wall pulmonary 4 2 md %26 as 5 1 and control the lungs blood musculature points thoracic"}, {"title": "11.02.1. The Lungs as Organs", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall/11.02.1. The Lungs as Organs.html", "keywords": "pleural membranes"}, {"title": "11.02.2. Blood Supply to the Lungs", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall/11.02.2. Blood Supply to the Lungs.html", "keywords": ""}, {"title": "11.02.3. Lymphatics of the Lung", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall/11.02.3. Lymphatics of the Lung.html", "keywords": ""}, {"title": "11.02.4. Nervous Control of the Lungs and Thoracic Musculature", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall/11.02.4. Nervous Control of the Lungs and Thoracic Musculature.html", "keywords": "somatic sensory autonomic afferent motor responses efferent innervation"}, {"title": "11.02.5. Thoracic Anatomy", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall/11.02.5. Thoracic Anatomy.html", "keywords": "muscles diaphragm sternomastoid muscle movements abdominal major cage ventilatory scalene pectoralis intercostal rib thoracic"}, {"title": "11.02.6. Points to Remember", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.02. The Lungs & Chest Wall/11.02.6. Points to Remember.html", "keywords": ""}, {"title": "11.03. Mechanics of Ventilation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.03. Mechanics of Ventilation.html", "keywords": "lung anatomy medicine static physiology of 11 remember dynamic resistance chest respiratory to 3 wall pulmonary 03 4 airway 2 md on %26 compliance ventilation effects 1 and mechanics points"}, {"title": "11.03.1. Static Lung and Chest Wall Mechanics", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.03. Mechanics of Ventilation/11.03.1. Static Lung and Chest Wall Mechanics.html", "keywords": "lung measurement thorax relationships static inspiratory elastic hooke's curve of rib interactions volume curves significance tension during pressure volumes chest capacities surface wall law hysteresis pulmonary disease physiological total -- composition change distensibility recoil cage pressures compliance surfactant ventilation expiratory and the pressure-volume lungs diaphragm-abdomen mechanism relaxation nature maximum gradients components spirometry"}, {"title": "11.03.2. Dynamic Lung and Chest Wall Mechanics", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.03. Mechanics of Ventilation/11.03.2. Dynamic Lung and Chest Wall Mechanics.html", "keywords": "lung rate effort-independent pressure-flow tracheobronchial laminar frictional curve of dependence curves inflation dynamic resistance effort-dependent pressure isovolume to airways transitional regimens law frequency types peak airway time flow effect poiseuille's equation motion compliance turbulent gas exhalation limitation expiratory ventilation in cephalad and the nonelastic pressure-volume plateau bias mechanics or constants distribution"}, {"title": "11.03.3. Effects of Lung Compliance and Airway Resistance on Ventilation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.03. Mechanics of Ventilation/11.03.3. Effects of Lung Compliance and Airway Resistance on Ventilation.html", "keywords": "muscular air costs of resistance pressure positive breathing effective weakness ventilatory pleural auto-peep effect trapping inspired on compliance gas ventilation pattern in and fatigue regional energy gradients work distribution"}, {"title": "11.03.4. Points to Remember", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.03. Mechanics of Ventilation/11.03.4. Points to Remember.html", "keywords": ""}, {"title": "11.04. Ventilation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.04. Ventilation.html", "keywords": "pattern%2c anatomy medicine partial gases physiology of 11 space remember alveolar respiratory ventilatory 05 to 3 space%2c pulmonary 04 4 dead 2 md pressures %26 ventilation pattern 1 classification and points"}, {"title": "11.04.1. Partial Pressures of Respiratory Gases", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.04. Ventilation/11.04.1. Partial Pressures of Respiratory Gases.html", "keywords": ""}, {"title": "11.04.2. Classification of Ventilation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.04. Ventilation/11.04.2. Classification of Ventilation.html", "keywords": "hyperventilation partial carbon of volume space hypoventilation pressure alveolar to dioxide total physiological composition dead equation anatomical minute gas ventilation ratio measuring and tidal or"}, {"title": "11.04.3. Ventilatory Pattern, Dead Space, and Alveolar Ventilation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.04. Ventilation/11.04.3. Ventilatory Pattern, Dead Space, and Alveolar Ventilation.html", "keywords": ""}, {"title": "11.05.4. Points to Remember", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.04. Ventilation/11.05.4. Points to Remember.html", "keywords": ""}, {"title": "11.05. Pulmonary Function Measurements", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.05. Pulmonary Function Measurements.html", "keywords": ""}, {"title": "11.06. Pulmonary Blood Flow", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.06. Pulmonary Blood Flow.html", "keywords": ""}, {"title": "11.07. Gas Diffusion", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.07. Gas Diffusion.html", "keywords": ""}, {"title": "11.08. Oxygen Equilibrium & Transport", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.08. Oxygen Equilibrium & Transport.html", "keywords": ""}, {"title": "11.09. Carbon Dioxide Equilibrium & Transport", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.09. Carbon Dioxide Equilibrium & Transport.html", "keywords": ""}, {"title": "11.10 Acid-Base Regulation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.10 Acid-Base Regulation.html", "keywords": ""}, {"title": "11.11. Control of Ventilation", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.11. Control of Ventilation.html", "keywords": ""}, {"title": "11.12. Ventilation-Perfusion Relationships", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.12. Ventilation-Perfusion Relationships.html", "keywords": ""}, {"title": "11.13. Clinical Assessment of Acid-Base & Oxygenation Status", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.13. Clinical Assessment of Acid-Base & Oxygenation Status.html", "keywords": ""}, {"title": "11.14. Physiological Basis for Oxygenation and Lung Protection Strategies", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.14. Physiological Basis for Oxygenation and Lung Protection Strategies.html", "keywords": ""}, {"title": "11.15. Physiology of Sleep-Disordered Breathing", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.15. Physiology of Sleep-Disordered Breathing.html", "keywords": ""}, {"title": "11.16. Fetal & Newborn Cardiopulmonary Physiology", "url": "/Pulmonary Medicine/11. Respiratory Anatomy & Physiology/11.16. Fetal & Newborn Cardiopulmonary Physiology.html", "keywords": ""}, {"title": "12. Pulmonary Symptoms", "url": "/Pulmonary Medicine/12. Pulmonary Symptoms.html", "keywords": ""}, {"title": "Critical Care Medicine", "url": "/Critical Care Medicine.html", "keywords": "ethics transplantation critical medicine research%2c ultrasound | trauma%2c trauma surgery%2c disorders research scanning oncologic neurologic metabolic topics - md gastrointestinal endocrine renal%2c administration renal and hematologic toxicology cardiovascular surgery pharmacology endocrine%2c care"}, {"title": "Cardiovascular Disorders", "url": "/Critical Care Medicine/Cardiovascular Disorders.html", "keywords": ""}, {"title": "Critical Care Ultrasound Scanning", "url": "/Critical Care Medicine/Critical Care Ultrasound Scanning.html", "keywords": ""}, {"title": "Gastrointestinal Disorders", "url": "/Critical Care Medicine/Gastrointestinal Disorders.html", "keywords": ""}, {"title": "Hematologic and Oncologic Disorders", "url": "/Critical Care Medicine/Hematologic and Oncologic Disorders.html", "keywords": ""}, {"title": "Neurologic Disorders", "url": "/Critical Care Medicine/Neurologic Disorders.html", "keywords": ""}, {"title": "Pharmacology and Toxicology", "url": "/Critical Care Medicine/Pharmacology and Toxicology.html", "keywords": ""}, {"title": "Renal, Endocrine, and Metabolic Disorders", "url": "/Critical Care Medicine/Renal, Endocrine, and Metabolic Disorders.html", "keywords": ""}, {"title": "Research, Administration and Ethics", "url": "/Critical Care Medicine/Research, Administration and Ethics.html", "keywords": ""}, {"title": "Surgery, Trauma, and Transplantation", "url": "/Critical Care Medicine/Surgery, Trauma, and Transplantation.html", "keywords": ""}, {"title": "Signs & Symptoms", "url": "/Pulmonary Medicine/01. Obstructive Lung Disease/Index/Signs & Symptoms.html", "keywords": "disease lung index 1 3 medicine 2 md symptoms obstructive dyspnea 01 cough %26 wheezing pulmonary signs"}]